CClinicalTrials.gg
RecruitingNCT04758676Updated Jan 18, 2024

BIA Assessment of Polymyoneuropathy in Critically Ill Patients

An interventional study of Nutritional and physiotherapy protocol, BIA and Standard of care in Sepsis, Trauma and Respiratory Insufficiency, sponsored by University Hospital Ostrava. Recruiting at 2 sites in Czechia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-01-18.

Sponsored by University Hospital Ostrava · Not applicable, Interventional, and Diagnostic

From the registry’s dates

  • Primary completion was expected by Feb 2024, 2 years 7 months ago, but the record still lists the study as recruiting.
  • Started Mar 2021; still recruiting 5 years 7 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The aim of the study is to monitor and evaluate changes in body composition, with a special emphasis on muscle mass, in the context of polyneuromyopathy of critically-ill patients at ICU, on artificial ventilation (duration of artificial ventilation at least 7 days), and subsequent comparison with the patient's condition in 12 weeks, as a part of Post-Intensive Care Syndrome (PICS) monitoring. The effect of the package (nutritional recommendations + physiotherapy protocol vs. standard of care) will be evaluated.

Read the detailed description

Intensive medicine keeps pushing its borders, and enables survival of critical illnesses, including the substitution of organ functions in patients with multiple organ dysfunction (MODS). Despite the improvements in short-term outcomes, the long-term prognosis and quality of life (long-term outcomes) in patients, who survived a critical condition at ICU, remain unfavorable. The long-term consequences may persist for months or even years.

Post-intensive care syndrome (PICS) represents a significantly limiting impairment in three areas: physical (polyneuromyopathy of critically-ill patients), cognitive (delirium), and mental (development of depressions and PTSD - post-traumatic stress disorder). It is especially the rapid deterioration of muscles caused with the catabolic effect of the illness itself during accentuated proteolysis, very negatively affects the muscle strength, inability to discontinue artificial ventilation in the patient, increase of infections, and prolongation of the ICU stay. It often results in the inability to discharge the patient into home care. Polyneuromyopathy affects up to 40% of critically-ill patients; at the greatest risk are especially patients in a serious catabolic state, with activated systemic inflammatory response, with microvascular ischemia, on corticosteroids, immobilized, and on long-term artificial ventilation. The prevention is difficult, as well as monitoring of the lean body mass (LBM), especially in the muscle mass of critically ill patients, who are further affected with changes in hydration and fluid leak.

BIA - bioelectric impedance is a non-invasive technique, which is able, on the basis of impedance, to evaluate body composition (muscles, fat, total body fluid), determine hydration (ratio of extracellular and intracellular fluid, fluid retention); another prognostic marker is also the phase angle. It helps to evaluate markers of nutrition, basal energetic metabolism.

The BIS Multiscan 5000 device measures 50 frequencies, which are used to create a Cole Plot, using a mathematical model. It enables obtaining data from bed-ridden critically-ill patients, using tetrapolar bioelectric impedance.

02

Conditions studied

  • Sepsis
  • Trauma
  • Respiratory Insufficiency
  • Surgery

Keywords

  • polymyoneuropathy
  • bioelectric impedance
  • post-intensive care syndrome
  • multiple organ dysfunction
03

In context

Respiratory Insufficiency

1,650 studies on the registry are indexed under Respiratory Insufficiency; 296 are open to participants now.

This study's planned enrollment of 60 is close to the median of 55 across 1,043 interventional studies indexed under Respiratory Insufficiency.

Browse Respiratory Insufficiency studies →

Lead sponsor

University Hospital Ostrava is the lead sponsor of 146 studies on the registry; 50 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Patients with respiratory insufficiency
  • Expected period of artificial ventilation of 7 days
  • Acute lung injury (ALI)
  • Acute respiratory distress syndrome (ARDS)
  • Acute exacerbation of chronic obstructive pulmonary disease (COPD)
  • Signed informed consent (may be signed by witnesses, if the patient is unconscious)

Exclusion criteria

Exclusion Criteria:

  • Patients with unfavorable prognosis for 12-week follow-up
  • APACHE Score >30
  • Metastasizing malignity
  • Patients after cardiopulmonary resuscitation (CPR) prior to admission
  • Cerebral edema
  • Cerebral trauma
  • Intracranial hypertension
  • Liver cirrhosis
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Nutritional and physiotherapy protocol, BIA

    Study subjects randomized into this study arm will be indicated for nutritional and physiotherapy protocol, based upon the obtained results of the measurements, using bioimpedance analysis.

    Other: Nutritional and physiotherapy protocol, BIA

  • Active comparator
    Standard of care

    Study subjects randomized into this study arm will be provided the current standard of care.

    Other: Standard of care

Interventions

  • OtherNutritional and physiotherapy protocol, BIA

    Study subjects will be treated using the nutritional and physiotherapy protocol, based upon the results of measurements, using bioimpedance analysis.

  • OtherStandard of care

    Study subjects will receive the current standard of care.

06

What researchers measure

Primary outcomes

  1. Body composition

    Body composition will be studied using bioimpedance analysis - comparison of skeletal muscle mass, fats, body fluids

    Time frame: 12 weeks

Secondary outcomes

  1. Changes in the albumin level

    Changes in the albumin level will be observed (in grams/Litre)

    Time frame: 12 weeks

  2. Changes in the prealbumin level

    Changes in the prealbumin level will be observed (in milligrams/Litre)

    Time frame: 12 weeks

  3. Changes in the C-reactive protein (CRP) level

    Changes in the C-reactive protein (CRP) level will be observed (in milligrams/Litre)

    Time frame: 12 weeks

  4. Changes in the presepsin level

    Changes in the presepsin level will be observed (in picograms/millilitre)

    Time frame: 12 weeks

  5. Comparison of muscle functions

    Comparison of muscle functions will be performed using dynamometry.

    Time frame: 12 weeks

Other outcomes

  1. Functional limitations - time up and go test (TUG)

    Functional limitations will be assessed with TUG (time up and go test) (in seconds)

    Time frame: 12 weeks

  2. Functional limitations - spirometry - forced vital capacity (FCV)

    Functional limitations will be assessed with spirometry - forced vital capacity (FCV) (volume)

    Time frame: 12 weeks

  3. Functional limitations - spirometry - forced expiratory velocity (FEV1)

    Functional limitations will be assessed with spirometry - forced expiratory velocity in one second (FEV1) (velocity)

    Time frame: 12 weeks

  4. Cognitive state

    Cognitive state of study subjects will be assessed with the presence of post-traumatic stress disorder (PTSD)

    Time frame: 12 weeks

07

Study locations

2 of 2 sites recruiting
  • University of Ostrava, Department of Physiology and Patophysiology
    Ostrava, Moravian-Silesian Region 70300, Czechia
    • Karin Petřeková, Mgr., Ph.D. · Contact · karin.petrekova@osu.cz · 0042055346
    • Karin Petřeková, Mgr., Ph.D. · Principal investigator
    • Iva Chwalková, Mgr. · Sub investigator
    Recruiting
  • University Hospital Ostrava
    Ostrava, Moravian-Silesian Region 70852, Czechia
    • Jiří Hynčica · Contact · jiri.hyncica@fno.cz · 0042059737
    • Marcela Káňová, MD,Ph.D. · Principal investigator
    • Vojtěch Vodička, MD · Sub investigator
    • Klára Rusková, Mgr. · Sub investigator
    • Ivana Nytra, Mgr. · Sub investigator
    • Martina Stodůlková, DiS. · Sub investigator
    • Ján Šida, Mgr. · Sub investigator
    Recruiting
08

References and documents

Individual participant data

Plan to share: No — There is no plan to make individual participant data available to other researchers.

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 18, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04758676
Lead sponsor
University Hospital Ostrava
Collaborators
University of Ostrava
Responsible party
Sponsor
First posted
Feb 17, 2021
Start date
Mar 1, 2021
Primary completion
Feb 29, 2024 (estimated)
Completion
May 31, 2024 (estimated)
Last update
Jan 18, 2024

Study contacts

Jiří Hynčica
Contact
jiri.hyncica@fno.cz
0042059737 ext. 2587
Marcela Káňová, MD, Ph.D.
principal investigator · University Hospital Ostrava

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion